We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
+39.57%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.03B
AUM Growth
+$88.2M
(+9.4%)
Cap. Flow
-$124M
Cap. Flow
% of AUM
-12.03%
Top 10 Holdings %
Top 10 Hldgs %
68.92%
Holding
48
New
–
Increased
4
Reduced
21
Closed
8
Top Buys
| 1 |
Cogent Biosciences
COGT
|
+$9.02M |
| 2 |
IDEAYA Biosciences
IDYA
|
+$7.49M |
| 3 |
Immunome
IMNM
|
+$1.5M |
| 4 |
Neurogene
NGNE
|
+$449K |
Top Sells
| 1 |
Kymera Therapeutics
KYMR
|
+$35.1M |
| 2 |
Replimune Group
REPL
|
+$26.4M |
| 3 |
HNGE
Hinge Health
HNGE
|
+$15.5M |
| 4 |
Biohaven
BHVN
|
+$10.3M |
| 5 |
Boston Scientific
BSX
|
+$9.16M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Scholar Rock
SRRK
$6.46B
| $145M | 14.15% |
3,904,456
-24,583
| -0.6% | -$860K |
|
2
Krystal Biotech
KRYS
$10.2B
| $117M | 11.36% |
661,388
-2,083
| -0.3% | -$312K |
|
3
Stoke Therapeutics
STOK
$1.86B
| $98.1M | 9.55% |
4,175,542
-200,389
| -5% | -$3.43M |
|
4
Zymeworks
ZYME
$1.81B
| $63.3M | 6.16% |
3,705,750
-444,877
| -11% | -$6.37M |
|
5
ADC Therapeutics
ADCT
$160M
| $62.7M | 6.1% |
15,666,731
| – | – |
|
|
6
Immunome
IMNM
$2.58B
| $58.8M | 5.72% |
5,023,385
+151,160
| +3% | +$1.5M |
|
7
LivaNova
LIVN
$4.4B
| $48.5M | 4.72% |
926,799
-7,472
| -0.8% | -$376K |
|
8
Regenxbio
RGNX
$631M
| $45.3M | 4.41% |
4,693,389
-82,328
| -2% | -$728K |
|
|
AKRO
9
DELISTED
Akero Therapeutics
AKRO
| $35.5M | 3.45% |
747,818
-26,493
| -3% | -$1.28M |
|
10
Nurix Therapeutics
NRIX
$2.46B
| $34M | 3.31% |
3,678,394
-54,494
| -1% | -$566K |
|
11
Beam Therapeutics
BEAM
$3.18B
| $33.7M | 3.28% |
1,387,559
-35,852
| -3% | -$713K |
|
|
12
Cogent Biosciences
COGT
$6.73B
| $31.7M | 3.09% |
2,209,118
+761,078
| +53% | +$9.02M |
|
13
Absci
ABSI
$1.67B
| $25.1M | 2.44% |
8,253,316
| – | – |
|
|
14
Neurogene
NGNE
$794M
| $22.5M | 2.19% |
1,299,022
+22,346
| +2% | +$449K |
|
|
ETNB
15
DELISTED
89bio
ETNB
| $21.7M | 2.11% |
1,473,136
-72,072
| -5% | -$735K |
|
|
16
IDEAYA Biosciences
IDYA
$3.54B
| $20.2M | 1.96% |
742,017
+309,523
| +72% | +$7.49M |
|
17
Annexon
ANNX
$947M
| $19.2M | 1.87% |
6,300,644
| – | – |
|
18
Fate Therapeutics
FATE
$346M
| $16.2M | 1.58% |
12,872,946
| – | – |
|
|
RAPT
19
DELISTED
RAPT Therapeutics
RAPT
| $14.3M | 1.39% |
552,594
-78,092
| -12% | -$1.02M |
|
20
Shattuck Labs
STTK
$607M
| $13.2M | 1.29% |
5,539,724
| – | – |
|
21
Solid Biosciences
SLDB
$946M
| $11.7M | 1.14% |
1,899,342
-16,584
| -0.9% | -$97K |
|
|
SLN
22
Silence Therapeutics
SLN
$486M
| $11.2M | 1.09% |
2,164,777
| – | – |
|
23
Nuvation Bio
NUVB
$2.04B
| $11.2M | 1.09% |
3,031,009
| – | – |
|
24
Keros Therapeutics
KROS
$215M
| $8.74M | 0.85% |
552,506
| – | – |
|
25
Celldex Therapeutics
CLDX
$3.02B
| $8.46M | 0.82% |
327,008
-16,018
| -5% | -$371K |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO